Company Information

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE2079.80137.15 (+7.06 %)
PREV CLOSE ( ) 1942.65
OPEN PRICE ( ) 1957.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 20430
TODAY'S LOW / HIGH ( )1956.75 2085.90
52 WK LOW / HIGH ( )1228 2649.95
NSE2077.25130.5 (+6.7 %)
PREV CLOSE( ) 1946.75
OPEN PRICE ( ) 1956.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 2077.25 (514)
VOLUME 278853
TODAY'S LOW / HIGH( ) 1954.25 2087.00
52 WK LOW / HIGH ( )1227 2524
ChairmanR S Karnad
Managing DirectorBhushan Akshikar
Company SecretaryAjay Nadkarni
Executive DirectorJuby Chandy
Non Executive DirectorS Williams
Non Executive Independent DirectorPV Bhide
S Maheshwari
A N Roy
D Sundaram
Manu Anand
Incorporation Year : 13-11 1924

Registered Office :

Address : Gsk House, Dr. Annie Besant Road,Worli, Mumbai,
Maharashtra-400030 .

Phone : 022-24959595

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.